BioCorRx Inc. (BICX)

[Jon Boyz]

I understand what you are saying. Appreciate your taking the time to spell out your thoughts. I was actually delighted that BICX switched back to BICX 102. BICX 101 was going up against the bigger companies, and I thought it was a more likely losing proposition. Concerning its products, its products can’t reach the real finish line until FDA approval. Am I right? That takes time. So while it’s developing one product, it shouldn’t keep its options open on new products? I see the Narcam as a excellent move because it solidifies BICX’s foot in the door against the bigger boys (if it works out).